Regan J. Lauer - 01 Sep 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Chief Accounting Officer
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol: IBRX
Transactions as of: 01 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Sep 2023, 19:40:15 UTC
Previous filing: 28 Aug 2023
Next filing: 19 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IBRX	Common Stock	Options Exercise	$0	+32,872	+156%	$0.000000	53,902	01 Sep 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Restricted Stock Units	Options Exercise	$0	-32,872	-50%	$0.000000	32,872	01 Sep 2023	Common Stock	32,872		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2	Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.